Stock Analiz

biote Corp. BTMD

Medicinal Chemicals and Botanical Products · data as of November 13, 2026

$1.06Market cap $38M
Open the interactive analysis →

biote Corp. (BTMD) is a healthcare company listed in the US with a market value of about $38M. In the twelve months to September 30, 2026 it had revenue of $179M and net income of -$2M, a net margin of -1.1%.

Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is future growth (1/5).

Key numbers: a price to free cash flow of 5.2, a 5-year average ROIC of 95%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 88% above the current price.

About biote

biote is listed in the US and classified in medicinal chemicals and botanical products. Revenue went from $139M in 2021 to $192M in 2025, growth of about 8.4% a year. It was profitable in 4 of the last 5 years in our data. Its share count rose by 355% over three years (dilution for shareholders).

Score: 2.0 / 5

Value2/5
Future growth1/5
Track record1/5
Financial health2/5
Shareholder returns4/5

Checks passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • Profit margin improving
  • 5-year average ROIC above 12%
  • Positive free cash flow
  • Interest covered more than 5 times
  • Pays a dividend
  • 20% to 100% of free cash flow returned to shareholders

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF5.2
P/S0.2
P/B—
EV/EBITDA12.5
PEG—
Dividend yield3.05%
FCF yield19.4%
Shareholder yield11.9%
Intrinsic value vs. price+88%

Growth and quality

Revenue growth (1 yr)-2.5%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)5.0%
ROIC (5-yr avg.)95.0%
Profitable years (of last 10)4
Years paying a dividend5

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$179M$192M$197M$185M$165M$139M
Net income-$2M$27M$3M$3M-$969000$11M
Free cash flow$7M$30M$39M$27M-$9M$32M
EPS (diluted)$-0.07$0.74$0.09$0.13$-0.12—
Net margin-1.1%14.1%1.6%1.8%-0.6%8.0%
ROIC—62.9%364.0%25.7%-59.1%81.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is biote stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 88% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does biote pay a dividend?

Yes. The dividend yield is about 3.05%, and it has paid dividends for 5 years in our data.

Is biote a good stock to buy?

We do not give buy or sell advice. biote scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.